ImaRx' ultrasound agent ready for Phase II trials
This article was originally published in Clinica
A Phase II trial with ImaRx' vascular ultrasound contrast agent, MRX-115 Aerosomes, is due to begin in September. The multicentre trial, involving 80 patients in Europe and the US, follows the recent completion of Phase I clinical trials for myocardial perfusion (see Clinica No 650/51, p 28). ImaRx plans to pursue approval of MRX-115 for other indications such as liver and kidney perfusion, says company president Evan Unger.